Kalshi, the prediction market platform, has secured approval from the Commodity Futures Trading Commission to offer perpetual futures contracts. The news hit major US exchange operators hard, with shares sliding as traders sized up the potential competition.
What Kalshi's new product does
Perpetual futures are derivatives that let traders bet on the price of an asset without an expiration date. Unlike traditional futures, they don't settle on a set day — instead, they use a funding rate to keep the contract price close to the underlying asset. Kalshi's approval means it can now offer these contracts on events it already lists, like economic data releases or political outcomes. The CFTC greenlit the move after a review process, though the exact details of which contracts will launch first haven't been disclosed.
Why exchange stocks dropped
Shares of companies that run stock and futures exchanges fell on the announcement. Investors appear to view Kalshi's product as a direct threat to the volumes and fees those exchanges collect from their own derivatives businesses. The drop wasn't limited to one firm — the broader sector took a hit, suggesting the market sees this as a structural shift in the competitive landscape. Kalshi isn't a household name like the CME or ICE, but it has carved out a niche in event-based trading, and perpetual futures could let it poach traders who want more flexible positions.
What's at stake for traditional exchanges
Perpetual futures are a staple of crypto exchanges but haven't taken off on regulated US venues. If Kalshi manages to attract liquidity, it could pressure incumbents to innovate or cut fees. The CFTC's decision also signals a willingness to let newer platforms experiment with derivatives structures that blur the line between betting and hedging. For now, the exchange operators have few options — they can't block the approval, and launching their own perpetual products would require their own regulatory sign-offs.
Kalshi hasn't announced when it will start listing the contracts. Traders will be watching for the first batch to see if the product gains traction — and whether the stock selloff was justified or an overreaction.
